28 June 2021 - Medexus Pharmaceuticals today announced that it has received a Notice of Compliance from Health Canada to commercialise treosulfan, developed by medac in Canada, following the satisfactory review of the submission for the bifunctional alkylating agent.

Treosulfan will be marketed in Canada under the brand name Trecondyv and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic haematopoietic stem cell transplantation.

Read Medexus Pharmaceuticals press release